1-3 of 3
Lin Gu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Barry Paul, Jirí Minarík, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Z Usmani, Lin Gu, Michelle Robeson, Michael Murphy, Camille Renard, Christine Chen, Luděk Pour
Journal: Blood
Blood (2023) 142 (Supplement 1): 3383.
https://doi.org/10.1182/blood-2023-186997
Published: 2023
Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Barry Paul, Michaela Liedtke, Jorge Monge, Maria Chaudhry, Robert M. Rifkin, Mitul D. Gandhi, Jack Khouri, Andrew Kin, Tibor Kovacsovics, Moshe Y. Levy, Ann Mohrbacher, William Schmidt, David S. Siegel, Rebecca W. Silbermann, Anna Louise Byrne, Tina Ncube, Michael Murphy, Lin Gu, Nishanthan Rajakumaraswamy, Mark Chao, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2021-145903
Published: 2021
Journal Articles

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Lin Gu, MS, Guan Xing, PhD, Nishan Rajakumaraswamy, MD, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5468.
https://doi.org/10.1182/blood-2019-124541
Published: 2019